Lung cancer vaccine - Northwest Biotherapeutics

Drug Profile

Lung cancer vaccine - Northwest Biotherapeutics

Alternative Names: DCVax-LB; DCVax-Lung

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator Northwest Biotherapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Lung cancer
  • Phase Unknown Glioblastoma

Most Recent Events

  • 05 Jan 2017 Jonsson Comprehensive Cancer Center and National Cancer Institute plan a phase II trial for Glioblastoma (Combination therapy, Recurrent) in USA (Parenteral) (NCT03014804)
  • 30 Nov 2016 Investigation in Glioblastoma in USA (Parenteral) before November 2016
  • 06 Dec 2012 Preclinical development completed in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top